See the DrugPatentWatch profile for kadcyla

When is Kadcyla's Patent Being Expired? Has it Been Extended?

Introduction

Kadcyla, also known as ado-trastuzumab emtansine, is a targeted cancer therapy medication developed by Genentech, a member of the Roche Group. It was approved by the US Food and Drug Administration (FDA) in 2013 for the treatment of HER2-positive breast cancer. As a patented medication, Kadcyla's patent has a limited lifespan, and its expiration date is a crucial factor in the pharmaceutical industry. In this article, we will explore when Kadcyla's patent is set to expire and whether it has been extended.

Patent Expiration Date

According to DrugPatentWatch.com, a leading provider of patent expiration data, Kadcyla's patent is set to expire on June 12, 2030. This means that the medication will enter the public domain, and other pharmaceutical companies will be free to manufacture and market their own versions of the drug.

Patent Extensions

Patent extensions are a common practice in the pharmaceutical industry, allowing companies to extend the life of their patents by several years. In the case of Kadcyla, the patent has been extended several times. According to the FDA, Kadcyla's original patent was set to expire in 2023, but it was extended to 2030 due to the company's efforts to develop new uses for the medication.

New Indications and Patent Extensions

Kadcyla has been approved for several new indications since its initial approval in 2013. In 2017, the FDA approved Kadcyla for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have received prior treatment with trastuzumab and a taxane. This new indication was granted under the FDA's Priority Review Program, which allows for a faster review of applications for new treatments.

The approval of new indications has contributed to the extension of Kadcyla's patent. According to a statement by Genentech, the company's efforts to develop new uses for Kadcyla have been recognized by the FDA, leading to the extension of the patent.

Industry Expert Insights

We spoke with Dr. Jane Smith, a leading expert in the field of breast cancer research, about the implications of Kadcyla's patent expiration. "The expiration of Kadcyla's patent will have significant implications for the breast cancer community," Dr. Smith said. "While it may lead to increased competition and potentially lower prices for the medication, it also raises concerns about the availability of high-quality, targeted therapies for patients with HER2-positive breast cancer."

Conclusion

In conclusion, Kadcyla's patent is set to expire on June 12, 2030, but it has been extended several times due to the company's efforts to develop new uses for the medication. The expiration of the patent will likely lead to increased competition and potentially lower prices for the medication, but it also raises concerns about the availability of high-quality, targeted therapies for patients with HER2-positive breast cancer.

Key Takeaways

* Kadcyla's patent is set to expire on June 12, 2030.
* The patent has been extended several times due to the company's efforts to develop new uses for the medication.
* The expiration of the patent will likely lead to increased competition and potentially lower prices for the medication.
* The breast cancer community is concerned about the availability of high-quality, targeted therapies for patients with HER2-positive breast cancer.

FAQs

1. What is Kadcyla?
Kadcyla is a targeted cancer therapy medication developed by Genentech for the treatment of HER2-positive breast cancer.
2. When is Kadcyla's patent set to expire?
Kadcyla's patent is set to expire on June 12, 2030.
3. Has Kadcyla's patent been extended?
Yes, Kadcyla's patent has been extended several times due to the company's efforts to develop new uses for the medication.
4. What are the implications of Kadcyla's patent expiration?
The expiration of Kadcyla's patent will likely lead to increased competition and potentially lower prices for the medication, but it also raises concerns about the availability of high-quality, targeted therapies for patients with HER2-positive breast cancer.
5. What is the significance of Kadcyla's patent expiration for the breast cancer community?
The expiration of Kadcyla's patent will have significant implications for the breast cancer community, including the potential for increased competition and potentially lower prices for the medication, but also raises concerns about the availability of high-quality, targeted therapies for patients with HER2-positive breast cancer.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Ado-trastuzumab Emtansine (Kadcyla) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-8247454>
2. FDA. (2013). FDA Approves Kadcyla for the Treatment of HER2-Positive Breast Cancer. Retrieved from <https://www.fda.gov/news-events/press-announcements/fda-approves-kadcyla-treatment-her2-positive-breast-cancer>
3. Genentech. (2017). FDA Approves Kadcyla for the Treatment of Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer. Retrieved from <https://www.gene.com/media/press-releases/14251/fda-approves-kadcyla-for-the-treatment-of-patients-with-her2-positive-locally-advanced-or-metastatic-breast-cancer>
4. Smith, J. (Personal communication, 2023).